$700m payout to dabigatran patients

Boehringer Ingelheim (BI) said that it expects the settlement will resolve about 4000 cases against the company in the US, but is prepared to “vigorously defend" itself against anyone who doesn't accept the terms.

Following its US approval in 2010 for the prevention of stroke in patients with atrial fibrillation, there were reports of excessive bleeding which prompted post-market reviews by regulatory authorities around the world.

However, the findings of a year-long FDA review of more 134,000 patients aged 65 years or older were mostly consistent with earlier clinical trial results,